CoChat

Targeting inflammation in depression: Ketamine as an anti-inflammatory antidepressant in psychiatric emergency

Open access
Nikkheslat, Naghmeh · 2021 · Brain, Behavior, & Immunity - Health
Cited by 71

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Abstract

Major depressive disorder (MDD) is a common psychiatric disorder with multifactorial aetiology and complex pathophysiology. Despite availability of various pharmacological and non-pharmacological therapeutic strategies, treatment resistant depression (TRD) remains a significant challenge with specific concern for those patients with severe depressive symptoms in particular suicidal ideations who require immediate and effective intervention. Inflammation has been widely studied for its association with MDD and treatment response. Ketamine known as a dissociative anaesthetic has a novel rapid-acting antidepressant effect at lower doses. Anti-inflammatory actions of ketamine appear to play a role in mechanisms underlying its antidepressant effects. Considering the rapid antidepressant action of ketamine, this review provides a brief overview of antidepressant properties of ketamine as well as its effects on peripheral and central inflammation to better understand the mechanisms underlying the therapeutic action of ketamine as an anti-inflammatory antidepressant target in psychiatric emergency. Development of effective medications, which act rapidly with dual effect on both inflammation and MDD would be of a significant clinical importance for a successful and personalised treatment of inflammatory-induced TRD and suicidal thoughts and behaviour.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.bbih.2021.100383

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 45

  1. Andrade, 2017, Ketamine for depression, 4: in what dose, at what rate, by what route, for how long, and at what frequency?, J. Clin. Psychiatr., 78, e852, 10.4088/JCP.17f11738 · DOI · Paper page
  2. Ballard, 2015, Neural correlates of suicidal ideation and its reduction in depression, Int. J. Neuropsychopharmacol., 18, 10.1093/ijnp/pyu069 · DOI · Paper page
  3. Beilin, 2007, Low-dose ketamine affects immune responses in humans during the early postoperative period, British journal of anaesthesia, 99, 522, 10.1093/bja/aem218 · DOI
  4. Cattaneo, 2020, Whole-blood expression of inflammasome- and glucocorticoid-related mRNAs correctly separates treatment-resistant depressed patients from drug-free and responsive patients in the BIODEP study, Transl. Psychiatry, 10, 232, 10.1038/s41398-020-00874-7 · DOI · Paper page
  5. Chang, 2010, Lipoteichoic acid-induced TNF-α and IL-6 gene expressions and oxidative stress production in macrophages are suppressed by ketamine through downregulating Toll-like receptor 2-mediated activation oF ERK1/2 and NFκB, Shock, 33, 485, 10.1097/SHK.0b013e3181c3cea5 · DOI
  6. Chang, 2009, Inhibitory effects of ketamine on lipopolysaccharide-induced microglial activation, Mediat. Inflamm., 705379
  7. Chen, 2018, Rapid inflammation modulation and antidepressant efficacy of a low-dose ketamine infusion in treatment-resistant depression: a randomized, double-blind control study, Psychiatr. Res., 269, 207, 10.1016/j.psychres.2018.08.078 · DOI · Paper page
  8. Cruz, 2017, Anti-inflammatory properties of anesthetic agents, Crit. Care, 21, 67, 10.1186/s13054-017-1645-x · DOI · Paper page
  9. Cui, 2019, Crosstalk between inflammation and glutamate system in depression: signaling pathway and molecular biomarkers for ketamine's antidepressant effect, Mol. Neurobiol., 56, 3484, 10.1007/s12035-018-1306-3 · DOI
  10. Dale, 2012, Does intraoperative ketamine attenuate inflammatory reactivity following surgery? A systematic review and meta-analysis, Anesth. Analg., 115, 934, 10.1213/ANE.0b013e3182662e30 · DOI · Paper page
  11. De Kock, 2013, Ketamine and peripheral inflammation, CNS Neurosci. Ther., 19, 403, 10.1111/cns.12104 · DOI · Paper page
  12. Deutschenbaur, 2016, Role of calcium, glutamate and NMDA in major depression and therapeutic application, Progress in neuro-psychopharmacology & biological psychiatry, 64, 325, 10.1016/j.pnpbp.2015.02.015 · DOI
  13. Dundee, 1970, Ketamine as an induction agent in anaesthetics, Lancet, 1, 1370, 10.1016/S0140-6736(70)91273-0 · DOI
  14. Fourrier, 2018, Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo, Trials, 19, 447, 10.1186/s13063-018-2829-7 · DOI · Paper page
  15. Haas, 1992, Ketamine: a review of its pharmacologic properties and use in ambulatory anesthesia, Anesth. Prog., 39, 61
  16. Haroon, 2018, Antidepressant treatment resistance is associated with increased inflammatory markers in patients with major depressive disorder, Psychoneuroendocrinology, 95, 43, 10.1016/j.psyneuen.2018.05.026 · DOI · Paper page
  17. Himmerich, 2006, Successful antidepressant therapy restores the disturbed interplay between TNF-alpha system and HPA axis, Biol. Psychiatr., 60, 882, 10.1016/j.biopsych.2006.03.075 · DOI
  18. Ho, 2019, Ketamine and active ketamine metabolites regulate STAT3 and the type I interferon pathway in human microglia: molecular mechanisms linked to the antidepressant effects of ketamine, Front. Pharmacol., 10, 1302, 10.3389/fphar.2019.01302 · DOI
  19. Horowitz, 2014, Antidepressant compounds can be both pro- and anti-inflammatory in human hippocampal cells, Int. J. Neuropsychopharmacol., 18, 10.1093/ijnp/pyu076 · DOI · Paper page
  20. Jin, 2019, The role of BDNF in the neuroimmune Axis regulation of mood disorders, Front. Neurol., 10, 515, 10.3389/fneur.2019.00515 · DOI · Paper page
  21. Kawasaki, 1999, Ketamine suppresses proinflammatory cytokine production in human whole blood in vitro, Anesth. Analg., 89, 665, 10.1213/00000539-199909000-00024 · DOI
  22. Loix, 2011, The anti-inflammatory effects of ketamine: state of the art, Acta Anaesthesiol. Belg., 62, 47
  23. Miller, 2013, Conceptual confluence: the kynurenine pathway as a common target for ketamine and the convergence of the inflammation and glutamate hypotheses of depression, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 38, 1607, 10.1038/npp.2013.140 · DOI
  24. Miller, 2020, Trial failures of anti-inflammatory drugs in depression, The lancet. Psychiatry, 7, 837, 10.1016/S2215-0366(20)30357-6 · DOI
  25. Mischel, 2021, Esketamine: a drug to treat resistant depression that brings more questions than answers, J. Clin. Psychopharmacol., 41, 233, 10.1097/JCP.0000000000001395 · DOI
  26. Niesters, 2014, Ketamine for chronic pain: risks and benefits, Br. J. Clin. Pharmacol., 77, 357, 10.1111/bcp.12094 · DOI · Paper page
  27. Nikkheslat, 2018, Neuroendocrine abnormalities in major depression: an insight into glucocorticoids, cytokines and kynurenine pathway imbalances, chapter 3, 45
  28. Nikkheslat, 2017, Antidepressant actions on glucocorticoid receptors, chapter 27, 2, 279
  29. Orsolini, 2020, Understanding the complex of suicide in depression: from research to clinics, Psychiatry investigation, 17, 207, 10.30773/pi.2019.0171 · DOI · Paper page
  30. Pribish, 2020, A review of nonanesthetic uses of ketamine, Anesthesiology research and practice, 5798285
  31. Roussabrov, 2008, Effect of ketamine on inflammatory and immune responses after short-duration surgery in obese patients, Open Anesthesiol. J., 2, 10.2174/1874321800802010040 · DOI
  32. Savitz, 2017, Role of kynurenine metabolism pathway activation in major depressive disorders, Current topics in behavioral neurosciences, 31, 249, 10.1007/7854_2016_12 · DOI
  33. Sforzini, 2019, Inflammation associated with coronary heart disease predicts onset of depression in a three-year prospective follow-up: a preliminary study, Brain Behav. Immun., 81, 659, 10.1016/j.bbi.2019.07.023 · DOI
  34. Sial, 2020, Ketamine: the final frontier or another depressing end?, Behav. Brain Res., 383, 112508, 10.1016/j.bbr.2020.112508 · DOI
  35. Singh, 2016, Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study, Biol. Psychiatr., 80, 424, 10.1016/j.biopsych.2015.10.018 · DOI · Paper page
  36. Talbot, 2019, Ketamine for chronic depression: two cautionary tales, J. Psychiatry Neurosci.: J. Psychiatr. Neurosci., 44, 384, 10.1503/jpn.190073 · DOI
  37. Thakurta, 2012, Rapid response with ketamine on suicidal cognition in resistant depression, Indian J. Psychol. Med., 34, 170, 10.4103/0253-7176.101793 · DOI · Paper page
  38. Wang, 2015, The rapid antidepressant effect of ketamine in rats is associated with down-regulation of pro-inflammatory cytokines in the hippocampus, Ups. J. Med. Sci., 120, 241, 10.3109/03009734.2015.1060281 · DOI · Paper page
  39. Wilkinson, 2017, Cognitive behavior therapy may sustain antidepressant effects of intravenous ketamine in treatment-resistant depression, Psychother. Psychosom., 86, 162, 10.1159/000457960 · DOI · Paper page
  40. Yang, 2019, Inflammatory markers and treatment outcome in treatment resistant depression: a systematic review, J. Affect. Disord., 257, 640, 10.1016/j.jad.2019.07.045 · DOI · Paper page
  41. Yang, 2015, Serum interleukin-6 is a predictive biomarker for ketamine's antidepressant effect in treatment-resistant patients with major depression, Biol. Psychiatr., 77, 10.1016/j.biopsych.2014.06.021 · DOI · Paper page
  42. Yuhas, 2015, Immunomodulatory activity of ketamine in human astroglial A172 cells: possible relevance to its rapid antidepressant activity, J. Neuroimmunol., 282, 33, 10.1016/j.jneuroim.2015.03.012 · DOI
  43. Zhang, 2021, Immunoregulation and antidepressant effect of ketamine, Transl. Neurosci., 12, 218, 10.1515/tnsci-2020-0167 · DOI
  44. Zhou, 2018, Antidepressant effect of repeated ketamine administration on kynurenine pathway metabolites in patients with unipolar and bipolar depression, Brain Behav. Immun., 74, 205, 10.1016/j.bbi.2018.09.007 · DOI · Paper page
  45. Zunszain, 2013, Ketamine: synaptogenesis, immunomodulation and glycogen synthase kinase-3 as underlying mechanisms of its antidepressant properties, Mol. Psychiatr., 18, 1236, 10.1038/mp.2013.87 · DOI · Paper page

Cited by

See all 71

Metadata

Authors
Nikkheslat, N.
Venue
Brain, Behavior, & Immunity - Health
Publisher
Elsevier BV
Published
2021-12
Volume
18
Pages
100383
ISSN
2666-3546 (ISSN-L)
OpenAlex
W3213166294
Cited by
71
References
53
FWCI
4.38
Type
journal article
Language
en
Open access
gold
Licence
Funders
  • Wellcome Trust
  • Medical Research Council
  • King's College London
  • Medical Research Foundation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.